We caught up with Daniel Joe Lovell (University of Cincinnati School of Medicine, Cincinnati, OH, USA) to discuss the effectiveness of abatacept in juvenile idiopathic arthritis categories. The abstract ‘Response to Abatacept in JIA Categories: Results from the PRCSG/PRINTO JIA Abatacept Phase IV Registry’ (ABSTRACT NUMBER: 0714) was presented at the virtual ACR Convergence 2020, 5-9 November 2020.
Questions
- What is the evidence and rationale for the use of abatacept in the treatment of juvenile idiopathic arthritis (JIA)? (0:25)
- Where does abatacept fit into the treatment paradigm for JIA? (2:05)
- What were the aims and design of the PRCSG/PRINTO JIA abatacept phase IV registry? (3:12)
- What were the strengths and limitations of the study? (4:48)
- What have been the findings to date and how will they inform future clinical practice? (6:56)
Disclosures: D. J. Lovell has served on speakers’ bureaus for Bristol-Myers Squibb Company, Genentech and Wyeth; has received consulting fees from Takeda and Celgene; and has served on data and safety monitoring boards for Forest Research and the National Institutes of Health-NIAMS; Cincinnati Children’s Hospital Medical Center has received consulting fees from Abbott, AbbVie, AstraZeneca, Bristol-Myers Squibb Company, Centocor, F. Hoffman La-Roche, Genentech, GlaxoSmithKline, Janssen, Novartis, Pfizer, Regeneron, Roche, UBC, and Xoma for the work of D. J. Lovell; and has received research funding from the National Institute of Child Health and Human Development.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ACR 2020 Annual Meeting (Virtual).
